BET (bromodomain and extraterminal) inhibitors have been shown to inhibit tumor growth in a number of models, including acute myeloid leukemia (AML) (33, –, 37), prostate cancer (38), neuroblastoma (39), and breast cancer (40). The gene discussed is DNER; the disease is prostate carcinoma.